Imatinib mesylate (IM), a new tyrosine kinase inhibitor, specifically targets BCR-ABL, which brings revolutionary era to the treatment of CML (Druker 2002, Savage and Antman 2002). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.